Abexinostat

Abexinostat
Names
	IUPAC name 3-[(Dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide
	Other names PCI-24781; CRA-024781
Identifiers
CAS Number	783355-60-2 ; 783356-67-2 (HCl) ;
3D model (JSmol)	Interactive image;
ChEMBL	ChEMBL2103863 ;
ChemSpider	9924562 ;
ECHA InfoCard	100.241.399
KEGG	D10060 ;
PubChem CID	11749858;
UNII	IYO470654U ; T1E6TM0SVG (HCl) ;
CompTox Dashboard (EPA)	DTXSID30229005 ;
	InChI InChI=1S/C21H23N3O5/c1-24(2)13-17-16-5-3-4-6-18(16)29-19(17)21(26)22-11-12-28-15-9-7-14(8-10-15)20(25)23-27/h3-10,27H,11-13H2,1-2H3,(H,22,26)(H,23,25) Key: MAUCONCHVWBMHK-UHFFFAOYSA-N ; InChI=1/C21H23N3O5/c1-24(2)13-17-16-5-3-4-6-18(16)29-19(17)21(26)22-11-12-28-15-9-7-14(8-10-15)20(25)23-27/h3-10,27H,11-13H2,1-2H3,(H,22,26)(H,23,25) Key: MAUCONCHVWBMHK-UHFFFAOYAM;
	SMILES O=C(NO)c3ccc(OCCNC(=O)c2oc1ccccc1c2CN(C)C)cc3;
Properties
Chemical formula	C21H23N3O5
Molar mass	397.431 g·mol−1
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). verify (what is ?) Infobox references

Abexinostat (INN, formerly PCI-24781) is an experimental drug candidate for cancer treatment. It was developed by Pharmacyclics and licensed to Xynomic. As of 2013, it was in Phase II clinical trials for B-cell lymphoma. Pre-clinical study suggests the potential for treatment of different types of cancer as well.

Abexinostat exerts its effect as a pan-histone deacetylase inhibitor and inhibits RAD51, which is involved in repairing DNA double strand breaks.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.